We propose the use of macitentan as a promising therapeutic strategy able to target the ETAR-dependent transcriptional activity of GSDME, impairing the metastatic traits in cancer cells and the release of inflammatory cytokines, especially IL-6, one of the critical mediators of cross-compartment interaction. This evidence concerns the gene IL6 and cancer.